AbbVie (ABBV): 135 IPR Hearing Shifted Odds Favourably - Jefferies
Tweet Send to a Friend
Jefferies analyst, Jeffrey Holford, reiterated his Buy rating on shares of Abbvie (NYSE: ABBV) along with his price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


